Background
==========

Cancer is a major global public health problem. One in 4 deaths in the United States is due to cancer \[[@B1]\]. Lung cancer is comprising 17% of the total new cancer cases and 23% of the total cancer deaths \[[@B2]\]. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancer cases where adenocarcinoma is dominantly presented \[[@B3]\]. Conventional treatment of NSCLC has improved survival, but the 5-year survival rate is approximately 16% over the past 30 years \[[@B1]\]. Novel and effective methods are urgently required for lung cancer therapy.

Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the adult mammalian brain via activation of specific GABA receptors highly expressed in the central nervous system (CNS) \[[@B4],[@B5]\]. GABA receptors are composed of GABA~A~ and GABA~B~ receptors. GABA~A~ receptors are ligand-gated chloride channels composed of five subunits. These subunits are encoded by 19 different genes that have been grouped into eight subclasses based on sequence homology (α1--6, β1--3, γ1--3, δ, ϵ, θ, π, ρ1--3). GABA~B~ receptors are heterodimeric G-protein-coupled receptors (GPCRs) composed of GABBR~1~ and GABBR~2~ subunits which are both required for normal receptor functioning \[[@B6]\].

It has recently revealed that GABA and its receptors also exist in non-neuronal peripheral tissues and organs, indicating that GABA exerts physiologic effects other than the inhibitory neurotransmitter property. In fact, GABA has been shown to be involved in the development of many tissues and organs, including the peripheral nervous system \[[@B7]\], the development of the palate \[[@B8]\], lung \[[@B9]\], pancreas \[[@B10]\], digestive tract \[[@B11]\], liver \[[@B12]\], chondrocytes \[[@B13]\], testicular cells \[[@B14]\] and even stem cells \[[@B15]\].

Given that GABA participates in the proliferation of various normal cell types and tissues, it is intriguing to consider the potential function of GABA in cancer cells. Recent studies gave the evidences that GABA and its receptors seemed to play critically regulative effects on many kinds of cancers \[[@B12],[@B16]-[@B31]\]. In most cases, the levels of GABA receptors accompanying other growth signaling components had significant changes in cancer cells. This raised the possibility that manipulating GABA receptor activity might inhibit tumor growth \[[@B25]\].

In this study, we tested the hypothesis that GABA receptor profiles modulate cancer survival. We thus investigated the gene expression of GABA receptor phenotypes in NSCLC tissues and paired non-cancerous tissues obtained from surgical patients to correlate the GABA receptor gene profiles with clinical outcome. To examine the specific effects of GABA receptor on lung cancer cell growth, we investigated the GABA receptor profiles in cancer cell lines and in normal human epithelial cell line in the presence and absence of exogenous administration of GABA.

Methods
=======

Cancer cell lines
-----------------

Human NSCLC cell lines H1299(adenocarcinoma), A549(adenocarcinoma), H520(squamous cell carcinoma), H460(large cell carcinoma) and normal human bronchial epithelial cell line BEAS-2B (ATCC, Rockville, Maryland) were cultured at 37°C with 5% CO~2~ in DMEM (Gibco, Beijing, China) supplemented with 10% FBS (Gibco, Beijing, China) without antibiotics.

MTT assays for cell proliferation
---------------------------------

To measure the proliferation of cells, the colorimetric 3-(4, 5-dimethyle thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assays (Sigma) were used in vitro. In the MTT assays, cells were seeded into 96-well plates (2 × 10^3^ cells per well), grown overnight, washed in PBS, and incubated with GABA (Sigma-Aldrich) at 0.1 μmol/L to 500 μmol/L in the presence or absence of 100 μmol/L picrotoxin (PTX, GABA~A~ receptor antagonist) or CGP35348 (CGP, GABA~B~ receptor antagonist), respectively. MTT was then added (10ug/well) for 4h. Formazan products were solubilized with DMSO, and the optical density was measured at 490 nm.

Tissues and subjects
--------------------

Sixty-one samples of NSCLC tissues and paired non-cancerous tissues (5cm away from tumor) were collected from the Thoracic Cardio Surgery Department of the First Affiliated Hospital of Guangzhou Medical College under full ethical clearance by the Guangzhou Medical College Ethics Committee for experimentation on human subjects. Informed written consent was obtained from the participants. All subjects were Chinese. The collected samples were immediately cut into small pieces and snap-frozen in liquid nitrogen until further use. All tumor tissue and paired non-cancerous tissue samples were pathologically confirmed.

RNA extraction and cDNA synthesis
---------------------------------

Total RNA from cell lines and liquid-nitrogen-frozen NSCLC tissue samples were extracted using Trizol reagent (Invitrogen). First-strand cDNAs were synthesized using primerscript RT reagent kit (Takara). Briefly, a mix of 2 ug RNA, 2 μl of 5× gDNA eraser buffer and 1 μl of gDNA eraser in a final volume of 10 μl with RNase free DH~2~O, was incubated at 42°C for 2 min to get rid of gDNA, and placed on ice for at least 1 min. Then 4 μL 5× Primerscript buffer, 1 μL Primerscript RT enzyme mix I, 1 μL RT primer mix, and 3 μL RNase free DH~2~O were added, and incubated at 37°C for 15 min followed by 85°C for 5 sec. The cDNA samples were stored at -20°C until use.

Primer design
-------------

Primers were designed using Primer Premier 5.0 and oligo 7 Software. Each primer pair was verified for gene specificity using Nucleotide Basic Local Alignment Search Tool from the GenBank non-redundant nucleotide sequence database (National Centre for Biotechnology Information, 2009, <http://www.ncbi.nlm.nih.gov/>). The sequence of each primer pair and the expected amplicon size were summarised in Table [1](#T1){ref-type="table"}.

###### 

Primer sequences, NCBI gene ID and amplicon size

  **Gene**    **NCBI gene ID**                **Sequence(5′---3′)**     **Amplicon size (bp)**
  ---------- ------------------ ----------- -------------------------- ------------------------
  GABR~A3~          2556           Sense      CCGTCTGTTATGCCTTTGTATT             165
                                 Antisense    TGTTGAAGGTAGTGCTGGTTTT               
  GABR~B3~          2562           Sense      GGAGATACCCCCTGGACGAGCA             196
                                 Antisense    GGATAGGCACCTGTGGCGAAGA               
  GABR~E~           2564           Sense      ATGCTTCTCCTAAACTCCGCC              248
                                 Antisense    CTTAAAACGCTTGCACCACTC                
  GABR~P~           2568           Sense       CGACCGTGTTATCAATGACC              120
                                 Antisense    CCCCAAACACAAAGCTAAAGCA               
  GABBR~1~          2550           Sense      CAGATAAATGGATTGGAGGGT              101
                                 Antisense   GAGAACTGAGACGGAGATAAAGAG              
  GABBR~2~          9568           Sense     GAGTCCACGCCATCTTCAAAAAT             108
                                 Antisense   TCAGGATACACAGGTCGATCAGC               
  18S rRNA       100008588         Sense       GCAATTATTCCCCATGAACG              123
                                 Antisense     GGCCTCACTAAACCATCCAA                

PCR
---

PCR was performed to pick out the genes expression in NSCLC cancer cell lines using Premix Taq® version 2.0 kit (Takara). The reaction condition was followed: initial denaturation at 95°C for 1 min; 35 cycles of 30 sec at 95°C; 30 sec at 58°C; and 30 sec at 72°C; followed by a final 3 min extension at 72°C. 3% Agarose gel was used in electrophoresis to separate the reaction products at 80V, 40min. After dyeing with ethidium bromide, the Gel Doc™ EZ Imager (BIO-RAD) was used for imaging.

RT-qPCR
-------

Real-time quantitative PCR was carried out in tissues cDNA samples using the SYBR® Premix Ex Taq™ reagent kit (Takara) through ABI PRISM®7900 HT Fast Real-Time PCR system (Applied Biosystems). Briefly, 2 μl of each cDNA product was amplified in a mixture containing 12.5 μl of 2 × SYBR® Premix Ex Taq™, 0.5 μl of 10 μmol/L PCR sense primer and the same quantitative antisense primer with dH~2~O in a final volume of 25 μL. The RT-qPCR was performed using the following parameters: initial denaturation at 95°C for 30 sec, 40 cycles of 5 s at 95°C, 30 s at 60°C. The dissolved curve was added to verify the specificity of amplified products. Wells with no template were included for each primer set as a negative control. In each experiment, samples were amplified in duplicate for each of the genes of interest and the reference gene. Only average CT values with a standard deviation \<0.5 were accepted.

Statistic analysis
------------------

The expression of each gene of interest was determined in relation to the reference gene 18S rRNA. The difference in the mean CT values of the duplicate samples against the reference gene was calculated to give the ΔCT. The relative quantitation value was then expressed as two times -ΔCT (2^--ΔCT^). Analysis of the 2^--ΔCT^ values data was performed using SPSS 13.0 followed by Paired-Samples *t* Test and Independent-Samples *t* Test where appropriate. Correlation analysis was carried out for GABA concentration and cell growth over time. Survival times between groups were displayed by Kaplan-Meier curves after a log-rank test. *P*\<0.05 was considered statistical significance.

Results
=======

Effect of GABA on cancer cell proliferation
-------------------------------------------

To examine the effects of administration of exogenous GABA on cancer cells proliferation in vitro, MTT assays were performed on the H1299 cells at broad range of concentrations of GABA(0.1-500 μmol/L). There was a dose- and time-dependent inhibition of cell proliferation with GABA (Figure [1](#F1){ref-type="fig"}A, B). The GABA concentration used was negatively correlated with the proliferation index (Figure [1](#F1){ref-type="fig"}C, r = -0.778, p \< 0.001; Figure [1](#F1){ref-type="fig"}D, r = -0.876, p \< 0.001). This inhibitory effects of GABA on cell proliferation was blocked by the use of CGP, a GABA~B~ receptor antagonist, while PTX, a GABA~A~ receptor antagonist, had no effect (Figure [1](#F1){ref-type="fig"}E, F). Similar results were observed in other NSCLC cell lines, such as A549, H520, H460 (data not show).

![**The effects of GABA and GABA agents on NSCLC cell.** H1299 cell proliferation was suppressed by GABA in a dose-dependent manner measured by MTT assays (Figure [1](#F1){ref-type="fig"}**A** and **C**). The inhibitory effects of GABA (100 μM/L) on H1299 cell growth were time-dependent (Figure [1](#F1){ref-type="fig"}**B** and **D**). This inhibitory effects of GABA (100 μM/L) on H1299 cell growth was blocked by CGP co-cultured but not by PTX (Figure [1](#F1){ref-type="fig"}**E** and **F**). Proliferation index was calculated as the ratio of the absorbance of cells incubated with GABA or GABA agents compare with negative controls (NC) which was defined as the cells cultured only with complete medium. N =3. \**P* \< 0.05, \*\* *P* \< 0.01, \*\*\* P \< 0.001 vs NC.](1479-5876-11-102-1){#F1}

GABA receptor profiles in NSCLC cell lines
------------------------------------------

The mRNA profile of GABA receptors was determined in NSCLC cell lines including H1299, A549, H520, H460 and BEAS-2B. The mRNA of human brain (a kind gift from Dr. He Junde, Department of neurosurgery in the same affiliation as ZX) was used as positive control and the normal lung bronchiolial epithelial cells BEAS-2B served as negative control. We found that six GABA receptor subunits were expressed in most NSCLC cell lines including GABA~A~ receptor subunits (GABR~A3~, GABR~B3~, GABR~E~, GABR~P~) and GABA~B~ receptor subunits (GABBR~1~ and GABBR~2~) (Figure [2](#F2){ref-type="fig"}A and B).

![**The mRNA profile of GABA receptors in NSCLC cell lines.** Figure [2](#F2){ref-type="fig"}**A** show that GABR~A3~, GABR~B3~, GABR~E~, GABR~P~, GABBR~1~ and GABBR~2~ ecpress in NSCLC cell lines. Brain expression acts as a positive control and BEAS-2B as a negative control. Figure [2](#F2){ref-type="fig"}**B** show three times of the PCR for gene relative expression. \* *P* \< 0.05, \*\* *P* \< 0.01.](1479-5876-11-102-2){#F2}

GABA receptor profiles in NSCLC tissues and paired non-cancerous tissues
------------------------------------------------------------------------

The gene expression of GABR~A3~, GABR~E~ and GABBR~2~ was significantly higher in primary NSCLC tissues than in the paired non-cancerous tissues (GABR~A3~, *t* = 2.227, *P* = 0.030; GABR~E~, *t* = 2.148, *P* = 0.036; GABBR~2~, *t* = 2.928, *P* = 0.005; Figure [3](#F3){ref-type="fig"}A, B and C). There was no significant difference observed in the expression of GABR~B3~ (*t* = -0.330, *P* = 0.742), GABR~P~ (*t* = 1.072, *P* = 0.288) or GABBR~1~ (*t* = -0.326, *P* = 0.746, Figure [3](#F3){ref-type="fig"}D, E and F) in the same tissues examined (Table [2](#T2){ref-type="table"}).

![**Gene expression levels in all NSCLC tissues and paired non-cancerous tissues.** Relative expression is presented as 2^-ΔCT^ ± S.E. The expression of 18S rRNA acts as reference gene. There is a significant increase in gene expression for GABR~A3~ (\**P* = 0.030, Figure [3](#F3){ref-type="fig"}**A**), GABR~E~ (\**P* = 0.036, Figure [3](#F3){ref-type="fig"}**B**) and GABBR~2~ (\*\**P* = 0.005, Figure [3](#F3){ref-type="fig"}**C**) in NSCLC tissues, with no difference in expression for GABR~B3~ (*P* = 0.742, Figure [3](#F3){ref-type="fig"}**D**), GABR~P~ (*P* = 0.288, Figure [3](#F3){ref-type="fig"}**E**) and GABBR~1~ (*P* = 0.746, Figure [3](#F3){ref-type="fig"}**F**). \* *P* \< 0.05, \*\* *P* \< 0.01.](1479-5876-11-102-3){#F3}

###### 

Comparison of GABA receptor gene relative expression between cancer and paired non-cancerous tissue

             **Normal(n = 61)**   **Cancer(n = 61)**   ***P*value**
  ---------- -------------------- -------------------- --------------
  GABR~A3~   1.647 ± 0.394        3.681 ± 0.853        0.030\*
  GABR~E~    2.054 ± 0.276        3.767 ± 0.883        0.036\*
  GABBR~2~   0.940 ± 0.236        3.315 ± 0.868        0.005\*\*
  GABR~B3~   3.585 ± 1.163        3.103 ± 0.792        0.742
  GABR~P~    3.147 ± 0.475        4.095 ± 0.760        0.288
  GABBR~1~   3.693 ± 0.538        3.413 ± 0.976        0.746

The data of GABA receptor gene relative expression were expressed as mean ± SE. Normal: Paired non-cancerous tissue. \* *P* \< 0.05, \*\* *P* \< 0.01.

Survival analysis in relation to GABA receptor gene profiles
------------------------------------------------------------

Using the median of 2^-ΔCT^ value as cutoff point, the data was divided into high and low expression for analysis. A high expression of GABBR~2~ in the lung tissue was associated with better survival as compared to those where low expression was detected (Figure [4](#F4){ref-type="fig"}B). However, a higher expression of GABR~A3~ was associated with a lower survival rate (Figure [4](#F4){ref-type="fig"}A). Smoking and TNM stage were also the important influential factors of decreased survival (Figure [4](#F4){ref-type="fig"}E, F). Expression of GABR~E~ and pathological grade did not appear to influence on survival time (Figure [4](#F4){ref-type="fig"}C, D).

![**Kaplan-Meier survival curves of NSCLC patients based on various influential factors.** Figure [4](#F4){ref-type="fig"}**A**, Overall survival rate in patients with high expression of GABR~A3~ was significantly lower than that in patients with high expression. Figure [4](#F4){ref-type="fig"}**B**, Overall survival rate in patients with high expression of GABBR~2~ was significantly higher than that in patients with low expression. Figure [4](#F4){ref-type="fig"}**E**, **F**, the smokers and the patients in advanced stage had a shorter survival time. Figure [4](#F4){ref-type="fig"}**C**, **D**, In spite of curve separated, GABR~E~ and pathological grade seemed to have no influence on survival time. \* *P* \< 0.05, \*\* *P* \< 0.01.](1479-5876-11-102-4){#F4}

GABA receptors profiles and selected clinical characteristics
-------------------------------------------------------------

The gene expression of GABR~A3~ was significantly higher in the NSCLC tissues in male patients, while the expression of GABBR~2~ was significantly higher than paired controls in the patients of female (Table [3](#T3){ref-type="table"}). It appeared that the gene expression of both GABR~A3~ and GABBR~2~ was higher in the patients with early stage of pathology, but not in the advanced stages.

###### 

GABRA3, GABRE and GABBR2 gene expression in NSCLC tissues compare with paired non-cancerous tissues

  **Variable**               **N(%)**    ***P*value**            
  -------------------------- ---------- -------------- --------- -----------
  Total                      61(100)       0.030\*      0.036\*   0.005\*\*
  Gender                                                         
   Male                      40(66)        0.040\*        NS         NS
   Female                    21(34)           NS          NS      0.008\*\*
  Age                                                            
   \<60                      36(59)           NS          NS       0.046\*
   \>60                      25(41)           NS          NS       0.014\*
  Smoking history                                                
   Yes                       23(38)           NS          NS         NS
   No                        38(62)           NS          NS       0.014\*
  Histotype                                                      
   Adenocarcinoma            43(70)           NS        0.049\*      NS
   Squamous cell carcinoma   18(30)           NS          NS       0.020\*
  Pathological Grade                                             
   I, II                     48(79)           NS          NS      0.008\*\*
   III                       13(21)           NS          NS         NS
  Pathological Stage                                             
   I, II                     47(77)        0.050\*        NS      0.008\*\*
   III                       9(15)            NS          NS         NS
   IV                        5(8)             NS          NS         NS

Pathological grade I: well differentiation, grade II: moderately differentiation, grade III: poorly differentiation. Pathological stage refers to the 7th Edition of TNM Classification of Malignant Tumors form UICC. *P*-value represents the gene expression of GABA receptor in NSCLC tissues compared with that in paired non-cancerous controls. NS: no significant difference. \**P* \< 0.05, \*\* *P* \< 0.01.

Discussion
==========

GABA and GABA receptors act as an inhibitory neurotransmitter in the mature CNS, but their functions in non-neuronal cells or tumor cells are not well addressed. Previous investigation has reported that GABA is significantly decreased in NSCLC tissues \[[@B26]\]. The previous observation maybe explained by our current findings demonstrating that GABA exerts inhibitory effects on human NSCLC cell. Our results further demonstrate that GABA~B~ receptors play an important role in mediating the GABA-inhibitory effects on NSCLC cells since the effects were blocked by using the antagonist CGP35348 specific for GABA~B~ receptor. Decreased GABA level might have resulted in impaired inhibitory effects on cancer cell proliferation as seen clinically \[[@B26]\]. A compensatory mechanism may be required by enhancing the expression of GABA~B~ receptors in order to redeem the impaired inhibitory effects.

The etiological factors of lung cancer are still not clear, but the tumor progression is associated with genetic changes and is reflected in phenotypic changes such as altered gene expression profiles. In this study, we found that the six genes of GABA receptors are expressed in most of NSCLC cells and tissues, including GABR~A3~, GABR~B3~, GABR~E~, GABR~P~, GABBR~1~ and GABBR~2~. These subunits might compose functional GABA~A~ and GABA~B~ receptor. These genetic changes suggest that GABA receptors have close relationship with NSCLC progression.

As for GABA~B~ receptors, it is now well accepted that GABA~B~ receptors assemble into heteromers composed of one GABBR~1~ and one GABBR~2~ subunit, which are both required for normal receptor function \[[@B6],[@B32]\]. Some recent reports have suggested that GABA inhibits neoplastic proliferation via GABA~B~ receptor \[[@B23],[@B26]\]. Since GABA~B~ receptor could strongly inhibit base level and isoproterenol-induced cAMP, p-CREB, cyclic adenosine monophosphate response element-luciferase activity and p-extracellular regulated kinase-1 (ERK1)/2 and effectively blocked DNA synthesis and cell migration. The inhibitory cancer cells arrest in G(0)/G(1) phase which is associated with down-regulation of intracellular cAMP level \[[@B33]\]. In our study, GABA inhibited proliferation of NSCLC cells in a dose-dependent and a time-dependent manner. This inhibitory effect could be blocked in the presence of GABA~B~ receptor inhibitor CGP35348. However, co-cultured with GABA~A~ receptor inhibitor picrotoxin, there were no significant proliferative effects on cancer cells versus control. These results imply that GABA inhibition of NSCLC cell proliferation was associated with GABA~B~ receptor which coincides with the report by Schuller and Al-Wadei \[[@B23],[@B26]\]. The high level expression of GABA~B~ receptor gene in NSCLC tissues compared with the adjacent non-tumor lung tissues, implicated that GABA and GABA~B~ receptor pathways could be a critical factor in regulation of NSCLC cells proliferation. This pathway might be a promising molecular target for the development of new therapeutic strategies for antineoplaston.

As for GABA~A~ receptors, it has been demonstrated that GABA~A~ receptors are usually composed of two α subunits, two β subunits, and one γ subunit, and sometime the γ subunit is replaced by other subunits, such as δ, ϵ, π and θ \[[@B34]\]. Different GABA~A~ receptor subunits have been detected in many cancer cell lines and tissues. Li et al. \[[@B12]\] detected overexpression of GABR~Q~ in hepatocellular carcinoma cell line HepG2, and half of the tested hepatocellular carcinoma tissues. Takehara \[[@B35]\] identified the overexpression of GABA receptor pi subunit (GABR~P~) in PDAC cells. In gastric cancer, more than five GABA~A~ receptor subunits were associated with stimulating KATO III cells \[[@B28]\]. The similar results that GABA~A~ receptors are related to cancer cell proliferation were reported in prostate cancer \[[@B29]\], breast carcinoma \[[@B36]\], even in normal human small airway epithelial cells \[[@B37]\]. These findings imply that the inward Cl^---^ ionic current transport and the activated mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) cascade via GABA~A~ receptors positively promotes cell proliferation. Our study revealed that the GABR~A3~ receptor gene was overexpression in NSCLC tissues compare with paired non-cancerous tissues, this was consistent with the study reported by Liu et al. \[[@B38]\]. In addition, beside overexpression of GABR~A3~ and GABR~E~ genes, the other GABA~A~ receptor genes expression in our study including GABR~B3~ and GABR~P~ were also detected in lung cancers, although there was no significant difference between NSCLC tissues and paired non-cancerous tissues. These GABA~A~ receptor subunits may form a functional pentameric chloride channel. We observe that the overexpression GABR~A3~ and GABR~E~ genes were not associated with proliferative effects on cancer cells. This indecipherable phenomenon will lend us to take more investigations of their roles in lung cancers.

Furthermore, our clinical data analysis showed that both GABA~A~ receptors (GABR~A3~) and GABA~B~ receptor (GABBR~2~) genes were significantly expressed in the early pathological stage (stage I and II) of the lung cancer patients, and the expression was gone in stage III and IV. This suggests that high level of gene expression of these GABA receptors may be critical in inhibition of early stage of cancer cells and this regulatory effect got impaired in advanced stage. We speculate that therapeutic intervention approaches that enhance GABA receptors maybe beneficial in late stages of NSCLC patients.

We observe a correlation between the high expression of GABBR~2~ gene and the greater survival rate in patients with NSCLC. The overexpression of GABBR~2~ gene was mostly seen in female patients who had better outcome. This suggests that patients with higher level GABBR~2~ might have better outcome. This observation is consistent with previous in vitro data showing that high level GABBR~2~ gene expression is associated with inhibition of cancer cell proliferation \[[@B26],[@B39],[@B40]\].

In contrast, high level GABR~A3~ gene expression is correlated with cancer cell development \[[@B12],[@B35],[@B41]\], and thus these patients had worse outcome. We indeed showed that the higher gene expression of GABR~A3~ was mostly detected in those male patients who had a worse prognosis.

Our data was based on a relatively small sample size of 61 patients with NSCLC who were followed for 3--5 years. Our data suggests that the gene expression of certain GABA receptor subunits may be useful for prediction of NSCLC prognosis. We believe that a longer term follow-up study with larger sample size would be required to confirm our current findings.

Conclusion
==========

The present study has identified significant gene profiles of GABA receptors in NSCLC and the gene profiles are correlated with patients' survival. Exogenous administration of GABA can inhibit NSCLC growth by activation on GABA receptors. Our data suggests that GABA receptors can modulate cancer cell proliferation and their gene profiles may be able to help predict prognosis in patients with NSCLC.
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